Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07264426 · ClinicalTrials.gov registry record

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

A clinical trial of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, sponsored by argenx.

Recruiting
Registry status
200
Enrollment target
19
Study locations

NCT07264426 is a study of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy that is actively recruiting participants, run by argenx. The registered enrollment target is 200 participants, above the 150-participant average among 4 other CIDP trials with a reported enrollment target (33% higher). The trial reports 19 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07264426, a study of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, is actively recruiting participants, sponsored by argenx.

RECRUITING
Registry status
200 participants
Enrollment target
19
Study locations

Study Summary

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Conditions Studied

CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Interventions

  • BIOLOGICAL Efgartigimod PH20 SC

Study Locations (19)

Other

  • Jüdisches Krankenhaus Berlin - Berlin
  • Universitätsklinikum Düsseldorf - Düsseldorf
  • Universitätsklinikum Frankfurt - Frankfurt
  • UKGM - Universitätsklinikum Gießen und Marburg GmbH - Giessen
  • Universitätsmedizin Göttingen - Göttingen
  • Universitätsklinikum Hamburg Eppendorf - Hamburg
  • Neurologie Neuer Wall - Dr.Bredow & Partner - Hamburg
  • Medizinische Hochschule Hannover - Hanover
  • Universitatsklinikum des Saarlandes - Homburg
  • Universitätsklinikum Magdeburg A.ö.R. - Magdeburg
  • Universitätsklinikum Mannheim - Mannheim
  • Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg - Marburg
  • Mühlenkreiskliniken - Johannes Wesling Klinikum Minden - Minden
  • Friedrich-Baur-Institute München - München
  • Immanuel Klinik Rüdersdorf - Rüdersdorf
  • Diakonie-Klinikum Schwäbisch Hall gGmbH - Schwäbisch Hall
  • Universitätsklinikum Tübingen - Tübingen
  • Universitätsklinikum Ulm - Ulm

North Carolina

  • PPD Virtual - Wilmington

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-08-11
Est. Completion 2029-10

Sponsor

argenx

49 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07264426

The ClinicalTrials.gov registry entry for NCT07264426 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 4 other CIDP trials with a reported enrollment target (33% higher). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with CIDP appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.

NCT07264426 reports 19 study locations spanning 2 distinct geographic areas - top geographies include Other, North Carolina.

Frequently Asked Questions

What is clinical trial NCT07264426 about?

NCT07264426 is a clinical study titled "Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study". The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with...

What is the current status of trial NCT07264426?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-08-11. Estimated completion is 2029-10.

What conditions does trial NCT07264426 study?

This clinical trial studies the following conditions: CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy).

What interventions are being tested in trial NCT07264426?

The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).

Who is sponsoring clinical trial NCT07264426?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07264426 being conducted?

This trial has 19 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for CIDP

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

CIDP

All registered trials for this condition

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.